The editorial paper in Oncoscience discusses the potential of antibody-drug conjugates in treating gynecologic cancers, focusing on biologically aggressive tumors like uterine serous carcinoma and carcinosarcoma. Researchers from Yale University School of Medicine emphasize the importance of cytoreductive surgery and chemotherapy in treatment but note the high recurrence rate, necessitating multiple treatment combinations. The use of immunotherapy in conjunction with standard chemotherapy and targeted drugs shows promise in endometrial cancer patients. In a study on trastuzumab-deruxtecan, an antibody drug conjugate, researchers demonstrated its effectiveness against aggressive uterine tumors overexpressing HER2/neu. This research marks a new era in gynecologic cancer treatment.
Source link
Antibody-drug conjugate shows preclinical efficacy
